Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) EBITDA (2022 - 2025)

Prokidney (PROK) has disclosed EBITDA for 4 consecutive years, with -$38.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 21.31% to -$38.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$171.2 million, a 9.53% decrease, with the full-year FY2024 number at -$183.7 million, down 21.22% from a year prior.
  • EBITDA was -$38.5 million for Q3 2025 at Prokidney, up from -$39.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$20.7 million in Q2 2022 to a low of -$66.5 million in Q1 2022.
  • A 4-year average of -$40.5 million and a median of -$40.1 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 38.5% in 2023, then tumbled 113.02% in 2024.
  • Prokidney's EBITDA stood at -$30.2 million in 2022, then rose by 19.93% to -$24.2 million in 2023, then plummeted by 113.02% to -$51.6 million in 2024, then grew by 25.27% to -$38.5 million in 2025.
  • Per Business Quant, the three most recent readings for PROK's EBITDA are -$38.5 million (Q3 2025), -$39.7 million (Q2 2025), and -$41.4 million (Q1 2025).